Core Viewpoint - Jasper Therapeutics is advancing its clinical-stage antibody therapy, briquilimab, targeting mast cell-driven diseases, with promising data from recent studies and plans for further clinical trials in chronic spontaneous urticaria (CSU) and asthma [1][2]. Financial Results - For the fourth quarter of fiscal 2025, Jasper reported a net loss of $9.1 million, with a basic and diluted net loss per share of $0.32 [5][10]. - Total operating expenses for the quarter were $15.8 million, which included $11.4 million in research and development and $4.5 million in general and administrative expenses [5][10]. - Cash and cash equivalents as of December 31, 2025, totaled $28.7 million, a decrease from $71.6 million in the previous year [10]. Clinical Development Updates - Briquilimab has shown a 67% complete response rate in additional patients from the BEACON study at 12 weeks, with a mean UAS7 reduction of 31 points [5]. - In the open-label extension study, 75% of CSU participants achieved a complete response or well-controlled disease at 12 weeks [5]. - The company is finalizing dose selection for the Phase 2b portion of its planned Phase 2b/3 study in CSU, with patient enrollment expected to begin in the second half of 2026, pending capital availability [2][5]. Recent Investigations - Jasper completed an internal investigation into the lack of clinical response observed in previous BEACON data, confirming no issues with the drug product and providing recommendations for future studies [5]. - The investigation included a comprehensive review of manufacturing records, patient medical histories, and pharmacokinetics data [5]. Future Prospects - Preliminary data from the ETESIAN study indicated reductions in airway hyperresponsiveness and eosinophilic response after a single 180mg dose of briquilimab, supporting further development in asthma [5]. - Future clinical studies in asthma will depend on the competitive landscape, potential strategic partnerships, and capital availability [5].

Company Overview - Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing briquilimab, an antibody therapy targeting KIT (CD117) for mast cell-driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma [3]. Recent Developments - On January 8, Jasper reported updated data for briquilimab, indicating that 67% of additional patients treated in the BEACON Phase 1b/2a study achieved a complete response at 12 weeks, while 83% achieved a complete response by week 3 after the initial dose [2]. - The BEACON Phase 2b study in chronic spontaneous urticaria (CSU) is expected to begin in the second half of 2026, with topline data anticipated in 2027 [2]. Analyst Coverage - UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a price target of $1.50, citing competition in the space as a limiting factor for upside potential [1]. - The report emphasized that investors are likely seeking longer-term durability data and noted the limited near-term catalysts for the company [1].

Summary of Jasper Therapeutics FY Conference Call Company Overview - **Company**: Jasper Therapeutics (NasdaqCM:JSPR) - **Focus**: Development of briquilimab, a c-Kit inhibitor for chronic urticarias and other mast cell-driven diseases [1][2] Core Points and Arguments Product Development - **Briquilimab**: Demonstrated compelling Phase 1 data in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) [1][2] - **Upcoming Trials**: Phase 2B trial in CSU scheduled for the second half of the year [1][21] Competitive Landscape - **Current Competitors**: - Xolair: Established treatment for asthma and CSU, works by clearing IgE [2][3] - Rhapsido (Novartis) and Dupixent: Recent approvals for CSU, but they do not eliminate mast cells [3][35] - **Differentiation**: Briquilimab targets KIT signaling, leading to mast cell apoptosis, unlike competitors that leave mast cells intact [3][4] Clinical Trials and Results - **BEACON Trial**: - Phase 1b/2a study in CSU showing rapid disease control with significant reductions in serum tryptase and UAS7 scores [4][6][10] - Safety profile: Minimal serious adverse events (AEs) reported, with some mild reactions [11][14] - **SPOTLIGHT Trial**: - Focused on symptomatic dermographism and cold urticaria, showing rapid responses in patients [15][16] - **ETEOSIAN Study**: - Investigated briquilimab in allergic asthma, demonstrating reduced eosinophil recruitment and improved lung function [17][19] Future Plans - **Phase 2b/3 Study**: Planned for CSU with two active doses versus placebo, aiming for data by the end of next year [21][40] - **Expansion**: Potential studies in other mast cell-associated diseases like COPD and IBD [22] Financial Considerations - **Funding Needs**: Jasper is seeking financing to support upcoming studies, with equity financing being a probable option [40][41] - **Strategic Partnerships**: Open to exploring partnerships but acknowledges the lengthy process involved [41] Additional Insights - **Patient Considerations**: Patients prioritize efficacy and speed of response when considering new therapies, with briquilimab showing rapid onset of action [34] - **Market Positioning**: The company aims to position briquilimab as a versatile treatment option for both CSU and CIndU, simplifying treatment protocols for physicians [39] Conclusion Jasper Therapeutics is advancing its lead candidate briquilimab through clinical trials, aiming to differentiate itself in a competitive landscape by targeting mast cell biology directly. The company is preparing for significant upcoming studies while navigating funding and partnership opportunities to support its growth and development strategy.

Core Insights - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, an antibody therapy targeting KIT (CD117) for mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][3] Company Overview - Jasper is conducting clinical studies of briquilimab, which is a targeted aglycosylated monoclonal antibody that inhibits signaling through the KIT receptor, leading to mast cell depletion via apoptosis [3] - The company has reported positive clinical outcomes for briquilimab in patients with CSU, CIndU, and allergic asthma, demonstrating both efficacy and safety [3] Upcoming Events - Jasper will participate in the 46th Annual TD Cowen Healthcare Conference from March 2-4, 2026, with a presentation scheduled for March 2, 2026, at 3:50 PM EST in a fireside chat format [2]

Summary of Jasper Therapeutics Chronic Urticaria Data Update Webinar Company Overview - **Company**: Jasper Therapeutics (NasdaqCM: JSPR) - **Focus**: Development of briquilimab for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) Key Points and Arguments Industry and Product Development - **Briquilimab**: An antibody targeting the KIT receptor, showing promise in treating mast cell-driven diseases, including CSU and CIndU [4][5] - **Clinical Trials**: Updated data from the BEACON study and an open-label extension study were presented, indicating positive outcomes for briquilimab [4][5] Efficacy and Safety Data - **BEACON Study Results**: - Six out of eight patients receiving briquilimab achieved complete response (CR) by week three, and four out of six by week 12 [6][9] - Mean reduction of UAS7 scores was 31 points at week 12, indicating significant symptom relief [9][12] - Rapid onset of disease control was observed, with most patients showing improvement within two weeks [9][10] - **Open-Label Extension Study**: - 63 patients treated with briquilimab showed durable clinical responses, with 65% of CIndU patients achieving CR or partial response (PR) at week 16 [9][15] - A favorable chronic safety profile was reported, with low incidence of KIT-related adverse events [7][20] Future Plans - **Phase 2b Study**: - Expected to commence in the second half of 2026, involving 75 to 100 adult patients with CSU [8][20] - The study will evaluate two effective dose regimens versus placebo [20] - **Dose Selection**: - Ongoing analysis of current data will inform the final dose selection for the phase 2b study [24][55] - Consideration of weight-adjusted dosing to optimize efficacy [48][55] Competitive Positioning - **Differentiated Product Profile**: - Briquilimab's unique mechanism of action and favorable safety profile position it competitively against other therapies targeting the KIT receptor [18][19] - The company believes the data supports a compelling product profile for chronic urticarias [20] Financial Considerations - **Capital Requirements**: - Current capital is sufficient to support operations through mid-2026, but additional funding will be necessary for future studies [28] - **Partnership Opportunities**: - The company is open to potential partnerships to support broader development across multiple indications [34] Additional Important Information - **CEO Transition**: The change in leadership was driven by the need for a new direction as the company progresses into pivotal studies [24] - **Regulatory Considerations**: The company is preparing to engage with regulatory bodies regarding the phase 2b study design and dose selection [25][46] This summary encapsulates the critical insights from the Jasper Therapeutics webinar, highlighting the company's advancements in chronic urticaria treatment and future strategic directions.

Core Insights - Jasper Therapeutics reported positive clinical data for briquilimab, an antibody therapy targeting KIT for chronic spontaneous urticaria (CSU) and other mast cell-driven diseases [2][3][11] BEACON Study Results - In the BEACON study, 67% of additional patients (n=6) achieved a complete response at 12 weeks, with a mean UAS7 reduction of 31 points [1][5] - 83% of participants in the 240mg/180mg Q8W cohort achieved a complete response by week 3 [2][5] - The study is a randomized, double-blind, placebo-controlled Phase 1b/2a trial focusing on safety, tolerability, and clinical activity [4] Open Label Extension Study Results - In the open-label extension study, 58% of CSU participants (n=36) achieved a complete response at 12 weeks, and 75% achieved either a complete response or well-controlled disease [9][10] - The study included a median follow-up duration of 205 days for 63 patients, with no dose-limiting toxicities observed [10] Safety Profile - Briquilimab was well-tolerated in both studies, with low-frequency, low-grade adverse events related to KIT blockade, none resulting in discontinuations [6][10] Future Plans - The data from the BEACON and open-label extension studies are deemed sufficient to support dose selection for a planned Phase 2b study in CSU, expected to commence in the second half of 2026 [11]

Company Leadership Changes - Jasper Therapeutics has appointed Jeet Mahal as President and Chief Executive Officer, effective January 5, 2026, succeeding Ronald Martell [2][3] - Thomas Wiggans has been appointed as the Executive Chairperson of the Board of Directors [2][3] Strategic Focus and Development - The company is preparing to commence the registrational program for briquilimab, targeting mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) [3][4] - Mr. Mahal brings over thirty years of experience in the life sciences industry, with a focus on developing therapeutics and leading biotech companies through clinical trials [3][4] Upcoming Events - Jasper will host an investor webinar on January 8, 2026, at 8:00 a.m. ET to present updated data from the BEACON study and the open-label extension study in CSU and CIndU [2][5] - A live question and answer session will follow the formal presentation during the webinar [5][6] Product Development - Briquilimab is a targeted monoclonal antibody that inhibits signaling through the KIT receptor, aiming to deplete mast cells and address inflammatory responses in diseases like CSU and asthma [7][8] - The drug has shown efficacy and safety in clinical studies involving patients and healthy volunteers, with positive outcomes reported in CSU, CIndU, and allergic asthma [8]

Summary of Jasper Therapeutics Data Update Webinar Company Overview - **Company**: Jasper Therapeutics (NasdaqCM:JSPR) - **Date of Call**: December 2, 2025 Key Points Industry and Company Focus - **Industry**: Biotechnology, specifically focusing on treatments for chronic spontaneous urticaria (CSU) and allergic asthma - **Core Product**: Briquilimab, a drug targeting mast cells BEACON Trial Findings - **Unexpected Results**: In the BEACON trial for CSU, none of the 10 U.S. patients in Cohort 8 achieved complete response by week 12, contrasting with two out of three patients in EU sites who did respond, indicating potential issues with drug lot A34954 used in the U.S. [4][5] - **Investigation**: An internal investigation was launched, reviewing manufacturing records, drug handling, and patient data. No significant deviations were found in drug production or handling [5][10][11]. - **Patient-Specific Factors**: The investigation concluded that patient-specific factors likely caused the unexpected results, with many patients possibly not having CSU [11][17]. Redosing Data from BEACON - **Cohorts 8 and 9**: Patients were switched to a new drug lot (34955) during the trial, showing no changes in pharmacokinetics (PK) or pharmacodynamics (PD) measures after redosing [12][15]. - **Clinical Outcomes**: The drug effectively depleted mast cells, as indicated by reduced tryptase levels, but clinical responses were not observed in many patients, suggesting misdiagnosis [15][17]. ATESIAN Study Results - **Study Design**: The ATESIAN trial assessed briquilimab's safety and efficacy in patients with mild allergic asthma, focusing on allergen challenges [20][21]. - **Efficacy Observations**: A single 180 mg dose resulted in significant reductions in serum tryptase levels and improved FEV1 responses, indicating a sustained effect on both early and late asthmatic responses [22][24]. - **Safety Profile**: Briquilimab was well tolerated with no serious treatment-related adverse events reported, reinforcing its safety in asthmatic populations [24][26]. Future Directions - **Next Steps**: Jasper plans to report additional BEACON data and open-label extension data in Q1 2026, including efficacy and safety data from new patients [26][27]. - **Broader Asthma Studies**: The company is evaluating further studies to explore briquilimab's effects across different asthma endotypes, including T2 high and T2 low diseases [25][27]. Recommendations for Future Trials - **Patient Selection**: Emphasis on quality patient selection is crucial, with recommendations to involve certified specialists in diagnosing CSU to avoid misdiagnosis [18][49]. - **Larger Sample Sizes**: Increasing sample sizes in trials may help mitigate the impact of non-mast cell-driven patients [18][67]. Conclusion - **Overall Outlook**: Jasper Therapeutics is optimistic about briquilimab's potential in treating both CSU and asthma, with ongoing investigations and upcoming data expected to support its clinical efficacy and safety [72].

Core Insights - Jasper Therapeutics reported positive preliminary clinical data from the ETESIAN Phase 1b study of briquilimab, showing significant reductions in airway hyperresponsiveness and eosinophilic response in asthma patients [2][4][5] Group 1: ETESIAN Study Findings - A single subcutaneous 180mg dose of briquilimab resulted in substantial reductions in sputum eosinophils at both 6 weeks (1.88% to 0.44%) and 12 weeks (1.88% to 0.38%) [2][12] - Improvements in FEV1 were observed in both Early Asthmatic Response (EAR) and Late Asthmatic Response (LAR), with LAR %Max FEV1 improving by 10.4% at 6 weeks and 8.7% at 12 weeks compared to baseline [7][10] - The study demonstrated a favorable safety profile for briquilimab, with no dose-limiting toxicities and infrequent low-grade adverse events [14] Group 2: BEACON Study Investigation - Jasper completed an internal investigation into the lack of clinical response in the BEACON study, concluding that the unexpected results were likely due to patient selection issues rather than problems with the drug product [3][16] - The investigation revealed that 9 out of 10 patients did not have chronic spontaneous urticaria (CSU) as their symptoms were not mast cell-driven, which affected the efficacy results [16][17] - The company is confident that insights from this investigation will help minimize enrollment of patients without mast cell-driven diseases in future studies [17] Group 3: Future Developments - Jasper plans to further develop briquilimab for asthma treatment, supported by the positive data from the ETESIAN study and the favorable safety profile observed [4][20] - The company anticipates additional data from the BEACON study in Q1 2026, which will inform dose selection for the Phase 2b CSU study planned for mid-2026 [17][20]

Core Viewpoint - Jasper Therapeutics is hosting a webinar to discuss findings from the BEACON study and preliminary data from the ETESIAN study, focusing on briquilimab's potential in treating mast cell driven diseases [1][2] Group 1: Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, an antibody therapy targeting c-Kit (CD117) for chronic mast cell diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [3] - Briquilimab works by blocking stem cell factor from binding to the KIT receptor, leading to mast cell depletion and reducing inflammation associated with these diseases [3] - The company has demonstrated efficacy and safety of briquilimab in clinical studies involving patients and healthy volunteers, showing positive outcomes in CSU and CIndU [3] Group 2: Webinar Details - The webinar is scheduled for Tuesday, December 2, 2025, at 8:00 am ET, featuring presentations from Jasper management and Dr. Martin Metz, a leading investigator in the BEACON study [1][2] - A live Q&A session will follow the formal presentation, allowing for direct engagement with the audience [1]